Comparative Pharmacology
Head-to-head clinical analysis: FASTIN versus SUPRENZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FASTIN versus SUPRENZA.
FASTIN vs SUPRENZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sympathomimetic amine that promotes release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, suppressing appetite.
Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.
30 mg orally once daily in the morning, administered as a single dose.
Adults: 200 mg orally twice daily with meals.
None Documented
None Documented
Terminal elimination half-life is approximately 16-20 hours for the immediate-release formulation. With sustained-release forms, effective half-life may extend to 24-34 hours due to prolonged absorption. Clinical context: time to reach steady state is about 3-5 days.
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, allowing for twice-daily dosing.
Primarily renal (approximately 70-80% unchanged) and biliary/fecal (20-30% as metabolites). Urinary excretion is pH-dependent; acidic urine increases elimination.
Approximately 60-80% of a dose is excreted renally as unchanged drug, with 20-40% eliminated via biliary/fecal routes.
Category C
Category C
Sympathomimetic Anorectic
Sympathomimetic Anorectic